Janssen-Cilag to launch anti-cancer drug
Janssen-Cilag India, the research pharma division of Johnson & Johnson, will launch an anti cancer genetically engineered molecule, called farneycil transferese inhibitor or FTI, for the treatment of
Janssen-Cilag India, the research pharma division of Johnson & Johnson, will launch an anti cancer genetically engineered molecule, called farneycil transferese inhibitor or FTI, for the treatment of